DelveInsight’s, “Metastatic Renal Cell Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in the Metastatic Renal Cell Carcinoma pipeline landscape. It covers the Metastatic Renal Cell Carcinoma pipeline drug profiles, including Metastatic Renal Cell Carcinoma clinical trials and nonclinical stage products. It also covers the Metastatic Renal Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Metastatic Renal Cell Carcinoma emerging drugs, the Metastatic Renal Cell Carcinoma pipeline analysis report provides a 360° view of the Metastatic Renal Cell Carcinoma pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Metastatic Renal Cell Carcinoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Metastatic Renal Cell Carcinoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Metastatic Renal Cell Carcinoma clinical trials studies, Metastatic Renal Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Metastatic Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report
To explore more information on the latest breakthroughs in the Metastatic Renal Cell Carcinoma Pipeline treatment landscape of the report, click here @ Metastatic Renal Cell Carcinoma Pipeline Outlook
Metastatic Renal Cell Carcinoma Overview
Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 85% of neoplasms arising from the kidney. Renal cell carcinoma may remain clinically occult for most of its course. Only 10% of patients present with the classic triad of flank pain, hematuria, and flank mass. Patients with renal cell cancer (RCC) develop metastatic spread in approximately 33% of cases. The clinical management of patients with metastatic RCC is complicated by the lack of significant efficacy from available therapies. Common sites of metastases include the lung, liver, bone, brain, and adrenal gland, with case reports detailing the capacity of RCC to appear almost anywhere in the body. More than one organ system is often involved in the metastatic process. Metastases may be found at diagnosis or at some interval after nephrectomy. Approximately 20% to 50% of patients will eventually develop metastatic disease after nephrectomy. A shorter interval between nephrectomy and the development of metastases is associated with a poorer prognosis. Patients with metastatic RCC face a dismal prognosis, with a median survival time of only 6 to 12 months and a 2-year survival rate of 10% to 20%.
Latest Developmental Activities in the Metastatic Renal Cell Carcinoma Treatment Landscape
For further information, refer to the detailed Metastatic Renal Cell Carcinoma Unmet Needs, Metastatic Renal Cell Carcinoma Market Drivers, and Metastatic Renal Cell Carcinoma Market Barriers, click here for Metastatic Renal Cell Carcinoma Ongoing Clinical Trial Analysis
Metastatic Renal Cell Carcinoma Emerging Drugs Profile
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It was first approved by the FDA and EU in December 2014. Currently, it is in Phase II stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma.
Atezolizumab is a humanized IgG antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-L1 and PD-1 removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. Currently, it is in Phase III stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma.
TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator,that is currently being evaluated in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors (NCT04328740). TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment.
Metastatic Renal Cell Carcinoma Pipeline Therapeutics Assessment
There are approx. 40+ key companies which are developing the therapies for Metastatic Renal Cell Carcinoma. The companies which have their Metastatic Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Genentech.
Metastatic Renal Cell Carcinoma Pipeline Segmentation
Phases
Route of Administration
Molecule Type
Request a sample and discover the recent advances in Metastatic Renal Cell Carcinoma Ongoing Clinical Trial Analysis and Medications, click here @ Metastatic Renal Cell Carcinoma Treatment Landscape
Scope of the Metastatic Renal Cell Carcinoma Pipeline Report
Dive deep into rich insights for drugs for Metastatic Renal Cell Carcinoma Market Drivers and Metastatic Renal Cell Carcinoma Market Barriers, click here @ Metastatic Renal Cell Carcinoma Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Metastatic Renal Cell Carcinoma Mergers and acquisitions, Metastatic Renal Cell Carcinoma Licensing Activities @ Metastatic Renal Cell Carcinoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services